Key Points {#d30e161}
==========

Hereditary angioedema (HAE) is a potentially life-threatening autosomal dominant disorder caused by deficiency of functional C1 esterase inhibitor (C1-INH).Four products are approved for the treatment of acute HAE in the USA, including one human plasma-derived C1-INH therapy, a recombinant human C1-INH product (rhC1-INH), a plasma kallikrein inhibitor and a bradykinin B2 receptor antagonist. Another human plasma-derived C1-INH therapy and danazol are approved for HAE prophylaxis.In randomized, controlled trials and open-label extension studies, rhC1-INH has demonstrated efficacy and safety for the treatment of acute attacks of HAE, with preliminary data showing possible utility for long-term HAE prophylaxis.

Introduction {#Sec1}
============

Hereditary angioedema (HAE) is a rare autosomal dominant genetic disease caused by a quantitative or qualitative deficiency of C1 esterase inhibitor (C1-INH) \[[@CR1], [@CR2]\]. The disease is characterized by recurrent episodes (attacks) of subcutaneous and submucosal swelling involving the skin, gastrointestinal tract and larynx \[[@CR1]--[@CR3]\]. Swelling of the larynx can cause fatal asphyxiation \[[@CR2]\]. Although the frequency of attacks can vary considerably in untreated patients (every 7--14 days on average), individual HAE attacks generally follow a predictable clinical course of symptoms developing gradually during the first 24 h and then subsiding during the subsequent 48--72 h \[[@CR1]\]. The prevalence of HAE is unclear; however, it is estimated to affect 1 in 50,000--100,000 individuals globally \[[@CR4]--[@CR6]\]. The onset of symptoms typically begins during childhood; symptoms often worsen during puberty, and HAE attacks generally continue throughout the life of the patient \[[@CR1]\]. HAE episodes usually occur without a predictable trigger; however, attacks can be precipitated by minor surgical or dental procedures or trauma, infection and stress \[[@CR7]\].

C1-INH is a serine protease inhibitor, which directly or indirectly inhibits several proteases associated with HAE attacks (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1], [@CR8]\]. C1-INH is a major inhibitor of several complement proteases such as C1r and C1s \[[@CR1], [@CR9], [@CR10]\] and contact proteases, including factor XIIa \[[@CR1], [@CR11]\] and kallikrein \[[@CR1], [@CR12]\], and a minor inhibitor of fibrinolytic proteases such as plasmin and factor XIa \[[@CR1], [@CR13], [@CR14]\]. In patients with HAE, uninhibited activation of the contact pathway due to insufficient levels of functional C1-INH results in unregulated cleavage of high molecular weight kininogen by kallikrein, leading to generation of excessive free bradykinin \[[@CR1], [@CR15]\]. Bradykinin is a potent vasoactive peptide, which mediates increased capillary permeability and oedema \[[@CR15], [@CR16]\]. There are three subtypes of HAE, generally classified according to associated levels and functional activity of C1-INH \[[@CR1]\]. Type I is the most prevalent, accounting for \~85 % of cases, and is defined by a quantitative deficiency of C1-INH protein \[[@CR1], [@CR17]\]. Type II HAE (\~15 % of cases) is associated with normal levels of C1-INH but deficient functional C1-INH activity, as the protein does not function properly. HAE with normal C1-INH (historically referred to as type III) is a rare, largely oestrogen-dependent form of HAE, mostly affecting females; the quantitative and functional levels of C1-INH are normal but patients experience angioedema attacks \[[@CR1]\]; the pathophysiology of this HAE subtype is poorly understood.Fig. 1Schematic representation of the pathways inhibited by C1 esterase inhibitor (C1-INH). C1-INH inhibits proteases in the complement, contact activation and fibrinolytic pathways. In hereditary angioedema, uninhibited activation of the contact pathway because of deficiency in functional C1-INH results in unregulated cleavage of high molecular weight kininogen by kallikrein, leading to generation of excessive free bradykinin, which is a potent vasoactive peptide. Proteolytic activities are indicated with *green arrows*, and steps inhibited by C1-INH are shown by *red bars*. From Zuraw \[[@CR1]\]. © 2008 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society \[[@CR1]\]

The management of HAE includes treatment of acute attacks, short-term or procedural prophylaxis (e.g. before dental procedures, minor surgery or endoscopy) and long-term prophylaxis to minimize the frequency and severity of recurrent attacks \[[@CR4], [@CR18], [@CR19]\]. Until 2008, management of HAE in the USA was limited to the use of fresh frozen plasma, antifibrinolytic agents, synthetic attenuated androgens and supportive care. Six products are currently approved by the US Food and Drug Administration (FDA) for the acute treatment (*n* = 4) or prophylaxis (*n* = 2) of HAE (Table [1](#Tab1){ref-type="table"}) \[[@CR20]--[@CR26]\]. These products include three C1-INH replacement therapies (two human plasma-derived C1-INH preparations \[Cinryze^®^ (Shire ViroPharma Inc., Lexington, MA, USA) and Berinert^®^ (CSL Behring GmbH, Marburg, Germany)\] and one recombinant human C1-INH preparation \[rhC1-INH\]), a plasma kallikrein inhibitor (ecallantide), a bradykinin B2 receptor antagonist (icatibant) and a synthetic attenuated androgen (danazol). In Europe, human plasma-derived C1-INH products have been used for more than three decades for the treatment of acute HAE, and icatibant and rhC1-INH have been approved since 2008 and 2010, respectively \[[@CR27]--[@CR29]\]. Although human plasma-derived C1-INH products have been available globally for many years, there are concerns, as with any plasma-derived product, about the potential risk of transmission of blood-borne pathogens, as well as supply issues \[[@CR27]\].Table 1US Food and Drug Administration (FDA)-approved agents for the treatment of hereditary angioedema (HAE) \[[@CR20]--[@CR26]\]Generic nameBrand nameDescriptionMode of administration and doseIndicationFDA approvalDanazolFormerly marketed as Danocrine^®^ in the USASynthetic attenuated androgenOral\
Initial dosing 100--200 mg daily. After favorable initial response (prevention), continuing dose should be minimized by decreasing dosage as tolerated based on clinical response and frequency of attacksPrevention of angioedema attacks of all types (cutaneous, abdominal, laryngeal) in males and females1976C1 esterase inhibitor (human)Cinryze^®^Plasma-derived C1 esterase inhibitorIV\
1000 U every 3 or 4 days\
Can be self-administeredRoutine prophylaxis against angioedema attacks in adolescents and adults with HAE2008C1 esterase inhibitor (human)Berinert^®^Plasma-derived C1 esterase inhibitorIV\
20 IU per kg body weight\
Can be self-administeredAcute abdominal, facial or laryngeal attacks of HAE in adolescents (aged ≥13 years) and adults2009EcallantideKalbitor^®^Plasma kallikrein inhibitorSC\
30 mg (3 × 10 mg injections); additional 30 mg within 24-h period\
Should be administered only by a healthcare providerAcute HAE attacks in patients aged ≥12 years2009IcatibantFirazyr^®^Bradykinin B2 receptor antagonistSC\
30 mg abdominal injection every 6 h (maximum, 3 doses every 24 h)\
Can be self-administeredAcute HAE attacks in adults (aged ≥18 years)2011C1 esterase inhibitor (human)Ruconest^®^rhC1-INHIV\
50 IU/kg (\<84 kg body weight) and 4200 IU (≥84 kg body weight); ≤2 doses every 24 h\
Can be self-administeredAcute attacks in adults and adolescents (investigated in patients aged ≥13 years) with HAE2014*IV* intravenous, *rhC1-INH* recombinant human C1 esterase inhibitor, *SC* subcutaneous

This review provides comprehensive information on the synthesis, pharmacokinetics and pharmacodynamics, efficacy and safety of intravenous rhC1-INH for the treatment of patients with HAE. In addition, the product characteristics and safety profile of rhC1-INH are compared with those of human plasma-derived C1-INH products, ecallantide and icatibant. The articles included in this narrative review were identified by a systematic search of PubMed using ("recombinant c1 esterase inhibitor" OR "recombinant C1 inhibitor") AND "hereditary angioedema" keywords for articles in English and consultation of recent review articles for general information on HAE prevalence, aetiology and treatment options. Bibliographies from included articles were reviewed manually for additional relevant studies.

Clinical Pharmacology {#Sec2}
=====================

Description {#Sec3}
-----------

rhC1-INH, a single-chain glycoprotein of 478 amino acids, is derived from milk of transgenic rabbits (\>99 % purity) using a 3-step Sepharose-based purification procedure including cation exchange chromatography, anion exchange chromatography and affinity chromatography \[[@CR30], [@CR31]\]. The recombinant human formulation was developed as an alternative to human plasma-derived C1-INH to eliminate the risk of transmission of human blood-borne pathogens, as well as to provide a reliable and scalable supply that is not dependent on human plasma donors \[[@CR8]\]. It is approved in the European Union and the USA for adults and adolescents (evaluated in individuals ≥13 years of age) for the treatment of acute angioedema attacks in patients with HAE due to C1-INH deficiency \[[@CR24], [@CR29]\]. The amino acid sequence of rhC1-INH is identical to that of endogenous human C1-INH but has differences in glycosylation patterns \[[@CR30]\].

Pharmacokinetics and Pharmacodynamics {#Sec4}
-------------------------------------

Population pharmacokinetics of rhC1-INH were evaluated by pooling data from six clinical studies in which blood samples were taken before and after intravenous administration of the drug in healthy volunteers, asymptomatic patients with HAE and patients with acute HAE attacks (294 administrations in 133 individuals; dose range 6.25--121 U/kg) \[[@CR32]\]. In this analysis, the half-life of rhC1-INH was determined to be \~3 h for a 100 U/kg dose (similar to the mean half-life of 2.4 h reported for a 50 U/kg dose \[[@CR24]\]); this interval is shorter than the intervals reported for human plasma-derived C1-INH products, which range from 22 to 56 h \[[@CR8], [@CR20], [@CR21], [@CR32]--[@CR34]\]. A higher degree of glycosylation on the rhC1-INH protein results in faster clearance of rhC1-INH from the circulation compared with human plasma-derived C1-INH protein \[[@CR32]\].

The pharmacokinetic profile of rhC1-INH was similar after single and multiple dosing \[[@CR32]\]. The final estimation of the volume of distribution was 2.9 L, which is consistent with the reported volume of plasma \[[@CR32], [@CR35]\]. Based on these analyses, a dosing scheme of 50 U/kg of rhC1-INH up to 84 kg body weight and a fixed dose of 4200 U for patients weighing ≥84 kg (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR32]\] was deemed appropriate to restore functional C1-INH levels. In a separate pharmacokinetic study, 12 asymptomatic patients with HAE receiving 6.25--100 U/kg of rhC1-INH on two occasions exhibited dose-dependent biological C1-INH activity with increasing plasma complement C4 levels (twofold after 12 h of administration of rhC1-INH 100 U/kg) and decreasing levels of its cleaved form \[[@CR31]\].Fig. 2Simulation of peak recombinant human C1 esterase inhibitor (rhC1-INH) concentrations for levels of the proposed dosing regimen (50 U/kg for up to 84 kg body weight and a fixed dose of 4200 U for patients with body weight \>84 kg). The 25th and 75th percentiles with the median values are represented as *boxes*; *ends of whiskers* represent 1.5 times the interquartile ranges (from the 25th and 75th quartiles). Any observations beyond 1.5 times the interquartile ranges are indicated as *open circles*, and the *dashed line* represents the lower limit of normal C1-INH (0.7 U/mL). Reprinted from Farrell et al. © 2013 The British Pharmacological Society \[[@CR32]\]

Clinical Efficacy {#Sec5}
=================

Acute Attacks {#Sec6}
-------------

The efficacy of rhC1-INH in the treatment of acute attacks in patients with HAE was evaluated in three randomized, double-blind, placebo-controlled studies and two open-label extension (OLE) studies (Table [2](#Tab2){ref-type="table"}) \[[@CR36]--[@CR40]\]. Two independent, randomized, double-blind, placebo-controlled studies were similarly designed: a North American study (C1 1205-01; 50 U/kg \[*n* = 12\] or 100 U/kg \[*n* = 13\] rhC1-INH vs placebo \[*n* = 13\]) and a European study (C1 1304-01; 100 U/kg rhC1-INH \[*n* = 16\] vs placebo \[*n* = 16\]) \[[@CR36]\]. Patients included in these trials presented with onset of HAE symptoms within \<5 h of enrolment and had an overall severity score of ≥50 mm on a visual analogue scale (VAS) \[[@CR36]\]. The primary efficacy endpoint was the median time to onset of symptom relief (≥20 mm decrease from baseline in the VAS score for two consecutive readings) \[[@CR36]\]. A pooled analysis of the two studies indicated a significantly faster onset of symptom relief for both doses of rhC1-INH, 50 U/kg (122 min; 95 % confidence interval \[CI\] 72--136; *P* = 0.013) and 100 U/kg (66 min; 95 % CI 61--122; *P* \< 0.001), versus placebo (495 min; 95 % CI 245--520). Although the median time to onset of relief was different for 50 versus 100 U/kg in the pooled analysis, the 95 % CIs overlapped for these dosing regimens, and Kaplan--Meier plots of both doses showed no significant difference in response. Median time to onset of relief at different anatomical locations (most attacks were peripheral or abdominal) with both doses of rhC1-INH (range 50--124 min) was faster than with placebo (range 243--560 min). In addition, treatment with both doses of rhC1-INH significantly reduced the median time to minimal symptoms compared with placebo (247, 266 and 1210 min for 50 and 100 U/kg rhC1-INH and placebo, respectively; *P* ≤ 0.001 vs placebo for both rhC1-INH doses) \[[@CR36]\].Table 2Efficacy and safety of recombinant human C1 esterase inhibitor (rhC1-INH) for the treatment of hereditary angioedema (HAE) \[[@CR36]--[@CR40]\]StudyPhaseStudy designPopulation/dosingEfficacy resultsSafetyC1 1205-01 (North American study) \[[@CR36], [@CR37]\]2/3Randomized, double-blind, placebo-controlled38 patients with HAE; 38 HAE attacks\
50 U/kg rhC1-INH (*n* = 12), 100 U/kg rhC1-INH (*n* = 13) or placebo (*n* = 13)Median time to onset of symptom relief (primary endpoint)^a^: 122, 68 and 258 min for 50 U/kg rhC1-INH, 100 U/kg rhC1-INH and placebo, respectively (50 mg, *P* = 0.013 vs placebo); 66 and 495 min for 100 U/kg rhC1-INH and placebo, respectively (*P* \< 0.001) in pooled efficacy data from North American and European studies\
Median time to minimal symptoms^b^: 247, 245 and 1101 min with 50 and 100 U/kg rhC1-INH and placebo, respectively (50 mg, *P* ≤ 0.001 vs placebo); 266 and 1210 min for 100 U/kg rhC1-INH and placebo, respectively (*P* \< 0.001) in pooled efficacy data from North American and European studiesPooled safety data from North American and European studies reported\
≥1 AE in 4 patients (33 %), 7 patients (24 %) and 14 patients (48 %) receiving 50 U and 100 U rhC1-INH and placebo, respectively\
Headache most common AE (10 %)\
1 patient (colitis) and 3 patients reported serious AEs in the rhC1-INH (100 U) and placebo groups, respectively (considered unrelated to the study drug)Open-label extension62 patients; 168 HAE attacks\
For 90 and 10 % of attacks, patients received 50 and 100 U/kg rhC1-INH, respectivelyMedian time to onset of symptom relief for first 5 HAE attacks^a^: 37--67 min\
Median time to minimal symptoms for first 5 HAE attacks^b^: 120--244 min39 patients (63 %) reported ≥1 AE\
Headache and nasopharyngitis most common AEs\
10 patients (14 %) reported serious AEs, of whom 8 patients reported HAE attacks; 7 serious AEs reported in 4 patients included vertigo, pneumonia, urosepsis occurring twice and itching of the lips and soft palateC1 1304-01 (European study) \[[@CR36], [@CR38]\]3Randomized, double-blind, placebo-controlled32 patients with HAE; for acute attacks\
100 U/kg rhC1-INH (*n* = 16) or placebo (*n* = 16)Median time to onset of symptom relief (primary endpoint)^a^: 64 min with 100 U/kg rhC1-INH and 520 min with placebo; 66 and 495 min for 100 U/kg rhC1-INH and placebo, respectively (*P* \< 0.001) in pooled efficacy data from North American and European studies\
Median time to minimal symptoms^b^: 480 min with 100 U/kg rhC1-INH and 1440 min with placebo; 266 and 1210 min for 100 U/kg rhC1-INH and placebo, respectively (*P* \< 0.001) in pooled efficacy data from North American and European studiesPooled safety data from North American and European studies reported (see safety data for North American study)Open-label extension57 patients; 194 attacks\
Vial-based dosing (2100 U) of rhC1-INH; 110, 68 and 15 attacks treated with 2100 U (1 vial), 4200 U (2 vials) and 6300 U (3 vials), respectivelyMedian time to onset of symptom relief^c^ for HAE attacks 1--5: 60, 65, 120, 60 and 61 min, respectively\
Median time to minimal symptoms^b^ showed consistent efficacy regardless of the number of attacks12 patients (28 %) and 9 patients (26 %) receiving 1 dose or \>1 dose of rhC1-INH 2100 U, respectively, reported ≥1 AE\
Headache and nausea were the most common AEs\
No serious AEs were reportedC1 1310 \[[@CR39]\]3Randomized, double-blind, placebo-controlled75 patients with HAE; for acute attacks\
50 U/kg for patients weighing \<84 kg, 4200 U for patients weighing ≥84 kg (*n* = 44) or placebo (*n* = 31)Median time to onset of symptom relief, based on TEQ score (primary endpoint)^d^: 90 min with rhC1-INH and 152 min with placebo (*P* = 0.031)\
Median time to onset of symptom relief, based on VAS score^c^: 75 min with rhC1-INH and 303 min with placebo (*P* = 0.003)\
Median time to minimal symptoms with rhC1-INH vs placebo: 303 vs 483 min, based on TEQ^e^ score (*P* = 0.078); 240 vs 362 min, based on VAS score^b^ (*P* = 0.005)≥1 AE reported in 4 patients (7 %) and 4 patients (22 %) in rhC1-INH and placebo groups, respectively, within 72 h postdose\
Most common AEs were respiratory, thoracic, mediastinal and gastrointestinal disorders\
1 serious AE (abdominal hernia) in rhC1-INH group \>70 days postdose (considered unrelated to the study drug)C1 1207 \[[@CR40]\]2Open-label, prophylaxis25 patients with HAE\
Once-weekly administration of rhC1-INH 50 U/kg for 8 weeksMean breakthrough attack rate was 0.4 attacks per week during 8-week period≥1 AE reported in 13 patients (52 %)\
4 AEs, mild in intensity, and considered possibly related to the study drug, were dry mouth, dizziness, hypotension and anxiety\
2 serious AEs were acute appendicitis and laryngeal oedema (considered unrelated to the study drug)*AE* adverse event, *TEQ* treatment effect questionnaire, *VAS* visual analogue scale^a^Interval until a ≥20 mm decrease from baseline in VAS score for 2 consecutive recordings at any eligible location^b^Interval until VAS score decreased to \<20 mm for all anatomical locations of an HAE attack^c^Interval until a ≥20 mm decrease from baseline in VAS score at any eligible location^d^Based on a set of 3 questions to assess symptom severity (7-point categorical scale from "much worse" to "much better")^e^Time between dosing and first time point at which patient reported a response of "yes" to TEQ question 3 ("At this moment, are your HAE attack symptoms minimal?") for all attack locations

The efficacy of rhC1-INH observed in the double-blind studies was maintained during treatment of subsequent HAE attacks during the OLE studies \[[@CR37], [@CR38]\]. For the first five HAE attacks during the North American OLE study (*n* = 62), the median time to onset of symptom relief (\>20 mm decrease from baseline in the VAS score) ranged from 37 to 67 min and the median time to minimal symptoms (VAS score \<20 mm) ranged from 120 to 244 min \[[@CR37]\]. Few attacks (10.0 %) required treatment with a second dose, and of these, most were oro-facial-pharyngeal-laryngeal attacks. Like the North American OLE study, the European OLE study (*n* = 57) supported the continued efficacy of rhC1-INH after repeated treatments for subsequent HAE attacks. The median times to onset of symptom relief (≥20 mm decrease from baseline in the VAS score) for HAE attack numbers 1 through 5 were 60, 65, 120, 60 and 61 min, respectively \[[@CR38]\]. By anatomical site, the fastest median time to symptomatic relief occurred with abdominal attacks (33 min), followed by peripheral attacks (61 min), oro-facial-pharyngeal-laryngeal attacks (120 min) and genitourinary attacks (480 min). The faster response observed with abdominal attacks compared with peripheral attacks is theorized to be due to faster resorption of fluid in the submucosal tissue compared with subcutaneous tissue.

In addition, a phase 3, randomized, double-blind, placebo-controlled study was conducted as part of an FDA biologics license application (Study C1 1310) \[[@CR39]\]. The study evaluated the efficacy and safety of rhC1-INH (50 U/kg for patients weighing \<84 kg and 4200 U for patients weighing ≥84 kg) for the treatment of acute attacks in patients with HAE. The most common primary attack locations (anatomical locations with the highest overall-severity baseline VAS scores) in this study were peripheral (44 %) and abdominal (37 %) \[[@CR39]\]. The primary endpoint, median time to onset of symptom relief, was significantly shorter in patients who received rhC1-INH compared with placebo, regardless of the instrument used to assess efficacy: the treatment effect questionnaire (TEQ) score (90 vs 152 min, respectively; *P* = 0.031; Fig. [3](#Fig3){ref-type="fig"}) \[[@CR39]\] or the VAS score (75 vs 303 min; *P* = 0.003). Treatment with rhC1-INH also reduced the median time to minimal symptoms compared with placebo (303 vs 483 min, respectively \[TEQ\]; *P* = 0.078; or 240 vs 362 min, respectively \[VAS\]; *P* = 0.005).Fig. 3Kaplan--Meier plot of time to onset of symptom relief based on Treatment Effect Questionnaire results. In this phase 3, randomized, double-blind, placebo-controlled study, patients with an acute attack of hereditary angioedema were treated with recombinant human C1 esterase inhibitor (rhC1-INH) (50 U/kg for patients weighing \<84 kg and 4200 U for patients weighing ≥84 kg). The *censor flags* indicate time points at which data were censored: patients who did not achieve the beginning of persistent symptom relief during the 24-h assessment period were censored at the last assessment time point (i.e. excluded from further efficacy analyses). Patients who received prohibited medications or open-label rescue rhC1-1NH before perceiving persistent symptom relief were censored at the last time point at which the Treatment Effect Questionnaire score was assessed before these medications were administered. Patients who did not experience minimal symptoms during the assessment period also were censored at the last assessment time point. Reprinted from Riedl \[[@CR39]\], Copyright 2014, with permission from American College of Allergy, Asthma & Immunology

Overall, the efficacy results from three randomized, double-blind, placebo-controlled studies and two OLE studies using a validated VAS instrument showed a consistent benefit of rhC1-INH in the treatment of acute angioedema attacks in patients with HAE \[[@CR36]--[@CR39]\]. Although direct comparisons are not possible because of study design and outcome measure differences, the efficacy data for rhC1-INH in the treatment of acute attacks of HAE appear to be similar to results observed in randomized, placebo-controlled trials of human plasma-derived C1-INH products \[[@CR41]--[@CR43]\]. The median times to onset of patient-reported symptom relief were 30 min with Berinert^®^ 20 U/kg versus 90 min with placebo (*P* = 0.0025) \[[@CR41]\] and 120 min with Cinryze^®^ 1000 U versus \>240 min with placebo (*P* = 0.02) \[[@CR42]\].

While not the focus of this review, it should be noted that the kinin pathway modulators ecallantide and icatibant are available as subcutaneous treatment options for acute HAE attacks. Ecallantide, a plasma kallikrein inhibitor, has been evaluated in two randomized, double-blind, placebo-controlled, phase 3 studies \[[@CR44], [@CR45]\]. In one study (*n* = 72), ecallantide 30 mg significantly reduced a composite treatment outcome score (range −100 \[significant symptom worsening\] to +100 \[significant symptom improvement\]) at 4 h postdose versus placebo (median score 50.0 vs 0.0, respectively; *P* = 0.004; primary endpoint) \[[@CR44]\]. There was no significant difference in the median time to significant improvement (patient-reported outcome of overall symptoms "a lot better or resolved") between ecallantide (165.0 min) and placebo (\>240 min; *P* = 0.1). In a second study (*n* = 96), a significant improvement from baseline in the mean symptom complex severity score (1 = mild; 2 = moderate; 3 = severe) 4 h postdose was reported for ecallantide 30 mg (−0.8 ± 0.6) versus placebo (−0.4 ± 0.8; *P* = 0.01; primary endpoint) \[[@CR45]\]. Ecallantide is licensed in the USA for the treatment of acute attacks of HAE in patients 12 years and older \[[@CR46]\].

Icatibant, a bradykinin B~2~ receptor antagonist, has been evaluated in three randomized, double-blind, phase 3 trials \[[@CR47], [@CR48]\]. One of the phase 3 studies (*n* = 56) failed to meet the primary endpoint. No significant difference between subcutaneous icatibant 30 mg and placebo in the median time to clinically significant relief (≥30 % decrease from baseline in the VAS score; primary endpoint) of the index symptom was observed (2.5 vs 4.6 h, respectively; *P* = 0.1), while in a second study (*n* = 74) of icatibant 30 mg versus tranexamic acid 3 g/day, the same primary endpoint was achieved (2.0 vs 12.0, respectively; *P* \< 0.001) \[[@CR47]\]. Given the failure to achieve the primary endpoint in the first study, another placebo-controlled study (*n* = 88) was conducted \[[@CR48]\]. In this third study, icatibant 30 mg significantly reduced the median time to cutaneous or abdominal attack symptom relief (50 % reduction from baseline in severity, assessed by a three-symptom \[skin swelling, skin pain, abdominal pain\] composite VAS score) versus placebo (2.0 vs 19.8 h; *P* \< 0.001; primary endpoint). Icatibant is licensed in \~40 countries, including the USA, for the treatment of acute HAE attacks in patients 18 years and older \[[@CR23]\].

Prophylaxis {#Sec7}
-----------

The efficacy of rhC1-INH (50 U/kg once-weekly administration) for long-term prophylaxis in patients with HAE experiencing frequent attacks (≥1 attack every 2 weeks) was evaluated in a pilot open-label study (*n* = 25) for 8 weeks (Table [2](#Tab2){ref-type="table"}) \[[@CR40]\]. The mean breakthrough attack rate was 0.4 attacks per week over the 8-week treatment period. Despite its short half-life, rhC1-INH appeared beneficial for long-term prophylaxis in patients with HAE. However, additional rigorous controlled studies are necessary to determine the true efficacy of rhC1-INH for long-term HAE prophylaxis \[[@CR25], [@CR42], [@CR49]\]. Both human plasma-derived C1-INH products have been used for short-term and long-term prophylaxis in HAE as reported in uncontrolled and observational studies \[[@CR19], [@CR25]\]. In addition, in a randomized, double-blind, placebo-controlled, crossover study (*n* = 22) in which Cinryze^®^ 1000 U or placebo was administered every 3--4 days for 12 weeks, with open-label Cinryze^®^ as rescue treatment for acute attacks, the frequency of HAE attacks was reduced by \~50 % during Cinryze^®^ versus placebo administration \[[@CR42]\]. Currently, in the USA, Cinryze^®^ is the only C1-INH agent approved for the routine prophylaxis of HAE attacks. A 12-week, dose-escalation study in 2014 indicated that some patients may require up to 2500 U of Cinryze^®^ every 3--4 days to prevent acute HAE attacks \[[@CR49]\].

Safety and Tolerability {#Sec8}
=======================

Adverse Events {#Sec9}
--------------

Safety data from randomized, controlled studies and OLE studies with rhC1-INH (Table [2](#Tab2){ref-type="table"}) support a favourable safety profile \[[@CR36]--[@CR40]\], and results were similar to those reported in clinical trials of human plasma-derived C1-INH products \[[@CR41], [@CR42]\]. Pooled safety data from the two randomized, placebo-controlled studies indicated that 33, 24 and 48 % of patients receiving 50 U/kg rhC1-INH, 100 U/kg rhC1-INH and placebo, respectively, had ≥1 adverse event (AE) \[[@CR36]\]. Headache was the most common AE in the rhC1-INH 100 U/kg group (10 %) and the placebo group (14 %); no headaches were reported in the 50 U/kg group. Headache and vertigo were considered related to rhC1-INH treatment. Colitis was reported in one patient after 31 days of rhC1-INH 100 U/kg treatment; it was not considered by the investigators to be related to the study drug and was the only serious AE reported in the rhC1-INH groups. In an additional phase 3, randomized, controlled study, 7 and 22 % of patients reported ≥1 AE in the rhC1-INH and placebo groups, respectively, within 72 h of dosing; one serious AE of abdominal hernia in the rhC1-INH group after 70 days of dosing was considered unrelated to the study drug \[[@CR39]\].

Safety data reported in the OLE studies were generally similar to those reported in the randomized controlled studies. In the North American OLE study, 63 % of patients reported ≥1 AE, and most AEs were mild to moderate in intensity \[[@CR37]\]. Twenty serious AEs were reported in ten patients, of which 13 AEs in eight patients were HAE attacks; seven serious AEs reported in four patients included vertigo, pneumonia, urosepsis (two episodes) and itching of the lips and soft palate with no signs of a systemic allergic reaction. In the European OLE study, additional dose(s) of rhC1-INH administered in a subset of patients did not increase the incidence of AEs (28 and 26 % of patients receiving one dose or ≥1 dose of rhC1-INH 2100 U, respectively), and no serious AEs were reported in this study \[[@CR38]\]. In the long-term prophylaxis study with rhC1-INH, 52 % of patients reported ≥1 AE; two AEs (acute appendicitis and laryngeal oedema) were serious, but neither was considered related to the study drug \[[@CR40]\].

An increased risk of thromboembolic complications has been reported with off-label, high-dose use of human plasma-derived C1-INH products, potentially mediated through increased levels of C1-INH, which can interact with fibrinolytic proteases, leading to a risk of thromboembolic adverse effects \[[@CR20], [@CR21], [@CR50]\]. However, clinical studies with rhC1-INH have not suggested an increased risk of thromboembolic complications \[[@CR36]--[@CR40]\]. Post hoc analyses of the effects of rhC1-INH on coagulation and fibrinolysis in patients with HAE who participated in the randomized, placebo-controlled North American study further supported that rhC1-INH treatment had no prothrombotic effects in patients with HAE receiving up to 100 U/kg \[[@CR36], [@CR51]\].

Regarding the safety and tolerability profile of other acute HAE therapies, the most common AEs reported for ecallantide (*n* = 255; pooled data) were headache (16 %), nausea (13 %), fatigue (12 %) and diarrhoea (11 %) \[[@CR22]\]. Anaphylaxis has been reported in 4.0 % of patients treated with ecallantide; thus, a boxed warning in the prescribing information indicates that ecallantide should only be administered by a healthcare provider with appropriate support to manage cases of anaphylaxis, and that patients should be closely monitored due to the similarity between symptoms of hypersensitivity reaction and an HAE attack \[[@CR22]\]. Unlike with ecallantide, no events of anaphylaxis have been reported in clinical trials of icatibant \[[@CR23]\]. The most commonly reported AEs with icatibant (*n* = 77; pooled data) have been injection-site reactions (97 %), pyrexia (4 %) and increased transaminase levels (4 %) \[[@CR23]\].

Immunogenicity {#Sec10}
--------------

Therapeutic proteins have the risk of eliciting an antibody response to the protein itself (anti-drug antibodies) or to impurities originating from the biological system used to produce the protein (e.g. anti-host-related impurities \[anti-HRI\]) \[[@CR52]\]. Because rhC1-INH is derived from the milk of transgenic rabbits and contains a small percentage (\<0.002 %) of HRI, it is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived products \[[@CR24]\]. Data from clinical trials support that rhC1-INH has a low potential to induce anti-drug antibodies or anti-HRI responses in patients with HAE \[[@CR52]\]. In a pooled analysis of five rhC1-INH clinical studies in symptomatic patients with HAE (*n* = 155; 424 administrations), 1.5 and 1.3 % of all pre-exposure and postexposure tests, respectively, were above the cutoff level (set using plasma samples from ≥50 patients with HAE naïve to rhC1-INH) of the screening assays for anti-C1-INH antibodies. However, these results were not accompanied by any clinical symptoms indicating hypersensitivity or any apparent changes in rhC1-INH efficacy. Anti-HRI antibodies were above the cutoff level in 0.7, 1.9 and 1.6--3.1 % of the screening assay tests before exposure, at 90 days after the first exposure and after repeat rhC1-INH treatment (22 or 90 days after repeat exposure), respectively. As with the anti-C1-INH antibody results, positive anti-HRI antibody results were not accompanied by clinical symptoms of hypersensitivity reactions.

The potential of rhC1-INH to induce immunoglobulin E (IgE) antibodies against rabbit milk proteins and other allergens was tested by a retrospective analysis of eight rhC1-INH clinical studies (130 patients with HAE and 14 healthy volunteers; 300 administrations) \[[@CR53]\]. Approximately 50 % of individuals were exposed more than once to rhC1INH (median, 2). A total of 24 individuals tested positive for select animal allergens (e.g. rabbit, cow, cat or horse dander) prior to rhC1-INH exposure. Five of these individuals had pre-existing anti-rabbit-epithelium IgE antibodies, and one of them experienced an anaphylactic reaction, the only such case observed in this study population. This individual received antihistamine and inhaled β-agonist therapy, with normalization of her condition within 1 h. None of these individuals had an increase in anti-rabbit IgE levels after rhC1-INH exposure. Of the 19 of 24 individuals who had pre-exposure positivity for select animal allergens other than rabbit, three (15.8 %) developed anti-rabbit IgE antibodies after rhC1-INH exposure; none of these individuals experienced allergic-type reactions during treatment with rhC1-INH.

Conclusions {#Sec11}
===========

HAE is a rare genetic disorder caused by a deficiency in functional C1-INH, and rapid replacement of functional C1-INH is a treatment strategy for managing HAE attacks. The recombinant technology used for the production of rhC1-INH addresses plasma supply concerns and potential risks for transmissible infections associated with human plasma-derived C1-INH products. Global, multicentre clinical studies have demonstrated that rhC1-INH is efficacious and well tolerated for the treatment of acute HAE attacks. Treatment with rhC1-INH has been shown to produce a rapid and sustained improvement in attack-related clinical symptoms. Preliminary data also suggest that rhC1-INH may be beneficial as long-term prophylaxis in patients with HAE; however, additional controlled studies are needed to validate this finding. A phase 2 prophylaxis study is ongoing, with anticipated completion in 2015. Currently, the clinical management of HAE involves individualized patient treatment plans using licensed medication options to terminate attacks, with additional prophylactic therapy in selected patients. The rapid onset of relief, durable efficacy and favourable safety profile associated with rhC1-INH treatment support its use in acute HAE treatment plans.
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